Michael Arbushites

2.2k citations

32 papers · 1.7k indexed · h-index 15

Impact in

Oncology top 2%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
Hematology top 5%
- Hematopoietic Stem Cell Transplantation

Papers in

Genetics 9
- Chronic Lymphocytic Leukemia Research 7
Oncology 23
- HER2/EGFR in Cancer Research 20
- Cancer Treatment and Pharmacology 12

Co-authors: Angelo Di Leo María Koehler Michael F. Press Richard S. Finn Steven H. Stein Cristina Oliva Judy Dering Henry Gómez
Journals: Journal of Clinical Oncology (15 papers)Blood (5 papers)Clinical Cancer Research (2 papers)Biology of Blood and Marrow Transplantation (2 papers)Molecular Oncology (1 paper)
Partner nations: United States Italy India

In The Last Decade

Michael Arbushites

31 papers receiving 1.6k citations

Peers

Countries citing papers authored by Michael Arbushites

Since Specialization

Citations

This map shows the geographic impact of Michael Arbushites's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Arbushites with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Arbushites more than expected).

Fields of papers citing papers by Michael Arbushites

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Arbushites. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Arbushites. The network helps show where Michael Arbushites may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michael Arbushites, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Arbushites Line = papers co-authored together Michael Arbushites links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft‐versus‐host disease British Journal of Haematology ·Michael A. Pratta, Sophie Paczesny, Gèrard Socié, O. A. Koya, Hao Liu, Sherry Owens, Michael Arbushites, Mark A. Schroeder, Michael Howell	2022	4
2	A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease Blood Advances ·Mark A. Schroeder, H. Jean Khoury, Madan Jagasia, Haris Ali, Gary J. Schiller, Karl Staser, Jaebok Choi, Leah Gehrs, Michael Arbushites, Ying Yan, Peter Langmuir, I.S. Mihaylova, Michael A. Pratta, Miguel‐Angel Perales, Yi‐Bin Chen, Gabrielle Meyers, John F. DiPersio	2020	72
3	Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial Blood ·Madan Jagasia, Miguel‐Angel Perales, Mark A. Schroeder, Haris Ali, Nirav N. Shah, Yi‐Bin Chen, Salman Fazal, Fitzroy W. Dawkins, Michael Arbushites, Chuan Tian, Laura Connelly‐Smith, Michael Howell, H. Jean Khoury	2020	173
4	Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease: Results from the Phase 2 REACH1 Trial Biology of Blood and Marrow Transplantation ·Madan Jagasia, Haris Ali, Mark A. Schroeder, Nirav N. Shah, Yi‐Bin Chen, Fitzroy W. Dawkins, Michael Arbushites, Chuan Tian, Miguel‐Angel Perales	2019	13
5	Ruxolitinib for the Treatment of Patients with Steroid-Refractory GVHD: An Introduction to the REACH Trials Immunotherapy ·Madan Jagasia, Robert Zeiser, Michael Arbushites, Tania Martín González, Brian Gadbaw, Nikolas von Bubnoff	2018	54
6	Trial in Progress: Gravitas-301, a Randomized, Double-Blind Phase 3 Study of Itacitinib or Placebo with Corticosteroids (CS) for the First-Line Treatment of Patients with Acute Gvhd (aGVHD) Biology of Blood and Marrow Transplantation ·Yi‐Bin Chen, Michael Arbushites, Tania Martín González, Ying Yan, Robert Zeiser	2018	3
7	Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: A pilot study Molecular Oncology ·Leonardo Tenori, Catherine Oakman, Wederson M. Claudino, Patrizia Bernini, Silvia Cappadona, 宣子小柳, Laura Biganzoli, Michael Arbushites, Claudio Luchinat, Ivano Bertini, Angelo Di Leo	2012	71
8	A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer Breast Cancer Research and Treatment ·Hope S. Rugo, A. Jo Chien, Sandra Franco, Alison Stopeck, Alexa Glencer, Soumi Lahiri, Michael Arbushites, Janet H. Scott, John W. Park, Clifford A. Hudis, Michael Toy, Maura N. Dickler	2011	36
9	Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer Journal of Clinical Oncology ·Richard S. Finn, Michael F. Press, Judy Dering, Michael Arbushites, María Koehler, Cristina Oliva, Lisa S. Williams, Angelo Di Leo	2009	144
10	Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens Annals of Oncology ·Kimberly Blackwell, Mark D. Pegram, Elizabeth Tan-Chiu, Lee S. Schwartzberg, Michael Arbushites, J. Maltzman, A. Chiba, S. D. Rubin, Steven H. Stein, Harold J. Burstein	2009	136
11	Final results from a phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2-overexpressing metastatic breast cancer (MBC). Cancer Research ·Maura N. Dickler, Simone Di Franco, Alison Stopeck, Weining Ma, Nam-Hoon Kim, Julia Lyandres, G. V. Williams, Soumi Lahiri, Michael Arbushites, María Koehler, HS Rugo	2009	12
12	First-line treatment with lapatinib plus paclitaxel versus paclitaxel alone for patients with HER2+ metastatic breast cancer (MBC): Quality-of-life (QOL) analysis using repeated measures and pattern mixture models Journal of Clinical Oncology ·Beth Sherrill, Yun Wu, Mayur M. Amonkar, Michael Arbushites, نجلاء محمد علي الحداد	2009	0
13	Progression-free survival (PFS) of patients with HER2-negative, estrogen-receptor (ER)-low metastatic breast cancer (MBC) with the addition of lapatinib to letrozole: Biomarker results of EGF30008 Journal of Clinical Oncology ·RS Finn, MF Press, Judy Dering, Allison Florance, Dominique Grange, Michael Arbushites, María Koehler, S. Johnston	2009	12
14	Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer Journal of Clinical Oncology ·Angelo Di Leo, Henry Gómez, Zeba Aziz, Zanete Zvirbule, José Bines, Michael Arbushites, Lorena Tigre [UNESP] Lacerda, María Koehler, Cristina Oliva, Steven H. Stein, Lisa S. Williams, Judy Dering, Richard S. Finn, Michael F. Press	2008	345
15	HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer Clinical Cancer Research ·Michael F. Press, Richard S. Finn, David Cameron, Angelo Di Leo, Charles E. Geyer, Ivonne Villalobos, Angela Santiago, Roberta Guzman, Armen Yuri Gasparyan, Yanling Ma, K. D. Danenberg, Anne Marie Martin, Lisa Williams, Cristina Oliva, Steven Stein, Robert Gagnon, Michael Arbushites, María Koehler	2008	134
16	Correlation of HER2 gene amplification, HER2 and EGFR expression (protein and mRNA) with lapatinib efficacy in women with metastatic breast cancer Journal of Clinical Oncology ·MF Press, RS Finn, Angelo Di Leo, David Cameron, Charles E. Geyer, Anne Marie Martin, B. Newstat, C. Kagenzi, Michael Arbushites, Martin Johannes Koehler	2008	8
17	A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2+ metastatic breast cancer (MBC) Journal of Clinical Oncology ·Hope S. Rugo, Sandra Franco, P.N. Munster, A. Stopeck, Weining Ma, Julia Lyandres, Soumi Lahiri, Michael Arbushites, María Koehler, Maura N. Dickler	2008	16
18	Identification of a 6 gene molecular predictor of lapatinib related benefit: From breast cancer cell lines to a phase III trial Journal of Clinical Oncology ·Joe W. Gray, Jinhuang Chai, Qi Zhang, Wen‐Lin Kuo, MF Press, Angelo Di Leo, P. P. Dorocher, Michael Arbushites, L. Williams, Martin Johannes Koehler	2008	3
19	Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancer Journal of Clinical Oncology ·Henry Gómez, Miguel A. Chavez, Dinesh Chandra Doval, Sandra Franco, Michael Arbushites, M. S. Berger, Michelle Casey, S. Stein, Tal Zaks, 曹松威	2007	10
20	2097 ORAL Biomarker analysis of lapatinib with paclitaxel versus paclitaxel as first-line treatment in 580 patients with metastatic breast cancer European Journal of Cancer Supplements ·Ying-Chun Chen, MF Press, Judy Dering, Henry Gómez, Zeba Aziz, Michael Arbushites, María Koehler, Cristina Oliva, B. L Evine, Angelo Di Leo	2007	2

About Michael Arbushites

Michael Arbushites is a scholar working on Genetics, Oncology, Hematology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 32 papers that have together received 1.7k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (20 papers), Cancer Treatment and Pharmacology (12 papers), Advanced Breast Cancer Therapies (10 papers), Chronic Lymphocytic Leukemia Research (7 papers), Hematopoietic Stem Cell Transplantation (7 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Acute Myeloid Leukemia Research (3 papers) and Acute Lymphoblastic Leukemia research (3 papers). The work is most often cited by research in Oncology (1.2k citations), Hematology (319 citations), Genetics (268 citations), Radiology, Nuclear Medicine and Imaging (423 citations) and Cancer Research (257 citations). Michael Arbushites has collaborated with scholars based in United States, Italy and India. Frequent co-authors include Angelo Di Leo, María Koehler, Michael F. Press, Richard S. Finn, Steven H. Stein, Cristina Oliva, Judy Dering, Henry Gómez, Zeba Aziz and Lisa S. Williams. Their work appears in journals such as Journal of Clinical Oncology, Blood, Clinical Cancer Research, Biology of Blood and Marrow Transplantation and Molecular Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact